Cara Therapeutics, Inc. (TVRD): יחס חוב להיוון בספרים

This chart illustrates the price trend for Cara Therapeutics Inc (TVRD), a developer of therapies for renal pathologies. The company is currently revising its development pipeline following unsuccessful tests and is optimizing expenses. Meanwhile, the company is implementing ESG principles and strict bioethical controls, with the 0.02 indicator characterizing the current metric. Financial stability remains low due to a lack of steady revenue and high capital expenditure.

This ratio determines the proportion of borrowed funds within the equity structure, measuring financial stability and credit default risk during economic cycle shifts. Analyzing the total debt of Cara Therapeutics Inc (TVRD) relative to its balance sheet capital allows for an assessment of the company's margin of safety in the face of potential late-stage clinical trial failures and fierce competition from pharma behemoths.